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Central regulation of vasopressin release  
It is generally accepted that vasopressin (VP) present in the 
neurohypophysis (NH) is synthesized in the hypothalamic neurons, located in 
the supraoptical nuclei and paraventricular nuclei and other accessory cell 
groups. After its synthesis, VP is packed in neurosecretory granules and 
transported by axons to the NH, where it is secreted into the circulation. In 
accordance with this hypothesis, the NH plays a role only as a VP storage site. 
In contrast with this opinion, another hypothesis suggests that dispersed 
cell cultures of isolated NH obtained from adult rats are capable of 
synthesizing and releasing VP. This observation on NH cultures is consistent 
with reports that the pituicytes of NH could be the sites of VP gene expression. 
The supernatant of the cell cultures contains VP that can be identified not only 
immunologically, but also mass spectrometrically.  
 
The role of the monoaminergic system 
Different neurotransmitters and neuropeptides are localized in the 
magnocellular portion of the hypothalamus. These compounds, secreted from 
the nerve terminals into the posterior lobe of the hypophysis, may play a role 
in the regulation of VP release. 
Of the above-mentioned neuroactive compounds, the monoaminergic 
compounds of the brain, histamine (HA), dopamine (DA), and serotonin (5-
HT), and the adrenergic system also play important roles in the regulation of 
VP secretion. 
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Interactions between galanin and monoaminergic compounds 
Galanin (GAL), as a peptide modulator, is physiologically involved in 
the regulation of the NH function and VP release, and related to the 
monoaminergic systems of the brain. 
It is generally believed that GAL and monoaminergic modulation occurs 
in both hypothalamic (somatodentritic) and NH (nerve terminal) regions and 
involves neuron-neuron and neuron-glial interactions. A majority of the 
literature data relating to this subject support the involvement of GAL and the 
monoaminergic system, via actions mainly at the somatodentritic level of the 
hypothalamus. The level of regulation of VP synthesis and release by GAL, 
monoaminergic compounds and their interactions that occur specifically at NH 
nerve terminals is less clear. Our experiments were designed to study the 
effects of these compounds on the synthesis and release of VP in vivo and in 




 Our experiments were designed to study the physiological effects of 
GAL, and to examine the interactions of GAL and the monoaminergic system 
relating to VP secretion. 
In our in vivo studies, the following questions were examined: 
1. Are there any differences between the effects of rat, porcine and human 
GAL, and various human GAL fragments on VP secretion following their 
intracerebroventricular (i.c.v.) or intravenous (i.v.) administration to rats? 
2. How can the different GAL compounds and fragments modify the increase 
in VP release in rats after an osmotic stimulus (2.5% NaCl solution)? 
3. How can the GAL treatment modify the VP concentration changes induced 
in rats by a non-osmotic stimulus (administration of HA)? 
4. Can the GAL antagonist galantid (M15) prevent the VP secretion changes 
induced by GAL? 
In our in vitro studies, the following questions were examined: 
1. Is there any direct effect of the GAL-ergic system on VP release in isolated 
rat NH tissue cultures?  
2. How can the GAL treatment modify the VP concentration changes induced 
in the supernatant medium of NH tissue cultures by an aspecific osmotic 
stimulus (administration of K+)? 
3. What are the effects of monoaminergic compounds on the VP 
concentration of the supernatant medium of NH tissue cultures? 
4. Can the different receptor-specific antagonists modify the effects of 
monoaminergic compounds? 
5. What are the effects of the interactions between GAL and the 
monoaminergic compounds on the VP secretion in rat NH tissue cultures?  
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Methods 
In vivo methods 
The experiments were performed on male rats ranging in weight from 
180 to 250 g. The animal care and research protocols were in accordance with 
the guidelines of our university and had been approved in advance by the 
appropriate ethical committee. The animals were subjected to ether anaesthesia 
during the operations. The rats had been cannulated for 7 days before the 
experiment. A stainless cannula was inserted into the right lateral ventricle.  
The following compounds were used: 
1. GAL compounds 
 (i.c.v. – 10 µl (22 µg)/animal; i.v. – 0.2 ml (220 µg)/animal) 
2. 2.5% NaCl solution  
 (i.p. 2 ml/100 g b.w., immediately before GAL administration) 
3. HA (i.p. 0.01 mg/100 g b.w., 15 min after GAL administration) 
4. Galantid (M15, a GAL antagonist)  
 (i.c.v. – 10 µl (0.22 µg)/animal, 15 before GAL administration) 
30 min following GAL administration, the rats were decapitated, and blood 
samples were collected. The plasma VP levels were measured by 
radioimmunoassay (RIA). Statistical analysis was performed by using the 
Tukey-Kramer multiple comparison test. 
 
 6 
In vitro methods 
Tissue culture method  
After decapitation, the pituitary of male Wistar rats was removed. The 
tissue was digested enzymatically (trypsin, collagenase, DN-ase I and II). The 
viability was 99-100%, and the cell count per ml was determined to be 2 x 106. 
The dispersed cells were placed into 24-well plastic plates coated with 
collagen. The VP contents of the cell culture supernatants were determined by 
RIA. Statistical analysis of VP concentrations was performed with the 
Kruskal-Wallis test.  
The following compounds were used:  
1. Rat GAL (10-6 M) 
2. Galantid (M15, a GAL antagonist, (10-13-10-7 M) 
3. Monoaminergic compounds: HA (10-6 M) 
  DA (10-6 M) 
5-HT (10-6 M) 
Adrenaline (ADR, 10-6 M) 
Noradrenaline (NADR, 10-6 M) 
4. HA antagonists: Mepyramine (MEP, H1-receptor antagonist, 10-6 M) 
 Cimetidine (CIM, H2-receptor antagonist, 10-6 M) 
Thioperamide (TPE, H3,4-receptor antagonist, 10-6 M) 
4. 5-HT antagonists: WAY-100635 (WAY, 5-HT1-receptor antagonist, 10-6 M) 
Ketanserin (KTS, 5-HT2-receptor antagonist, 10-6 M) 
Metergoline (MTG, 5-HT1,2-receptor antagonist, 10-6 M) 
5. ADR antagonists: Phentolamine (PTA, α1+α2-receptor antagonist, 10-6 M) 
 Corynanthine (CAT, α1-receptor antagonist, 10-6 M) 
 Yohimbine (YOB, α2-receptor antagonist, 10-6 M) 
6. NADR antagonists: Propranolol (PNL, β1+β2-receptor antagonist, 10-6 M) 
 Atenolol (ATL, β1-receptor antagonist, 10-6 M) 
 Pindolol (PDL, β1+β2-receptor antagonist, 10-6 M)
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Results and discussion 
1. Effects of galanin on vasopressin secretion 
There were no changes in the basal VP secretion after i.v. or i.c.v. GAL 
administration. I.c.v. GAL treatment partially or totally blocked the VP level 
enhancement induced by 2.5% NaCl or HA administration. There was no 
significant difference in the inhibitory effects of rat, porcine or human GAL. 
The human GAL 1-16 N-terminal fragment decreased the level of VP 
secretion. The GAL 16-30 C-terminal fragment was ineffective. This 
observation suggested that the active centre is localized in the N-terminal part 
of the GAL molecule. The GAL antagonist galantid (M15) administered 
before the GAL i.c.v. injection totally prevented the inhibitory effect of GAL 
on the increased plasma VP level following the administration of 2.5% NaCl 
solution or HA. 
Significantly and dose-dependently decreased content of VP was 
detected in NH tissue cultures media following the administration of 10-9–10-6 
M doses of GAL. 
Significantly elevated VP levels were measured after K+ administration. 
The enhancement of VP secretion could not be prevented by previous GAL 
treatment. The enhancing effects of K+ on hormone secretion is not dependent 
on the receptors, and we therefore concluded that there are GAL receptors on 
the membrane of the pituicytes of the isolated tissue cultures, and specific 
receptors are involved in the interactions between GAL and the 
monoaminergic system. 
 
2. Effects of histamine on vasopressin secretion 
Significantly increased levels of VP production were detected in the 
tissue culture media following HA administration, depending on the HA dose. 
The VP secretion elevation could be partially blocked by previous 
administration of the H1-receptor antagonist MEP or the H2-receptor 
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antagonist CIM. The H3–H4 receptor antagonist TPE did not influence the VP 
secretion increase induced by HA. MEP or CIM application after HA 
administration proved ineffective. We concluded that mainly the H1-and H2-
receptors are involved in the HA-induced increase of VP secretion, while the 
H3–H4-receptor antagonist TPE proved ineffective in isolated NH tissue 
cultures. The HA-induced elevation of the VP level was partially blocked by 
GAL administration before HA treatment. GAL administration after HA 
treatment did not decrease the enhancement of VP secretion. This 
phenomenon can be explained in that the 20-min preincubation period is 
probably long enough for the VP level-increasing action of HA, and thus GAL 
is ineffective. The results indicate that the HA-ergic control and GAL-HA 
interaction relating to VP secretion from the NH tissue in rats can occur 
independently of the hypothalamus, at the level of the posterior pituitary. 
 
3. Effects of dopamine on vasopressin secretion 
DA increased the VP level in the medium of isolated NH tissue cultures. 
The VP level elevations induced by DA were totally blocked by the previous 
administration of GAL. The DA-blocking effect of GAL was prevented by 
addition of the GAL receptor antagonist galantid (M15). Our results indicate 
that there are DA receptors in the cells of the NH (pituicytes), and that the DA-
ergic regulation and the GAL-DA interaction can occur independently of the 
hypothalamus, at the level of the posterior pituitary. 
 
4. Effects of serotonin on vasopressin secretion 
Significantly increased levels of VP production were detected in the 
tissue culture media following 5-HT administration, depending on the 5-HT 
dose. The VP secretion elevation could be partially blocked by previous 
administration of the 5-HT antagonist KTS or MTG. WAY did not influence  
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the VP secretion increase induced by 5-HT. Accordingly, we conclude that 
mainly the 5-HT2 receptors are involved in the 5-HT-induced increase of VP 
secretion in isolated NH tissue cultures. GAL administration before 5-HT 
treatment partially blocked the 5-HT-induced elevation of the VP level. GAL 
administration after 5-HT treatment proved ineffective. These results reveale 
that VP release from the NH is influenced by the 5-HT-ergic system directly at 
the level of the posterior pituitary. 
 
5. Effects of the adrenergic system on vasopressin secretion 
Significantly increased VP levels were detected in the tissue culture 
media following the administration of ADR or NADR, depending on the dose. 
The VP secretion elevation was totally blocked by the previous administration 
of PTA (an α1+α2-receptor antagonist) or CAT (an α1-receptor antagonist). 
YOB (an α2-receptor antagonist) did not influence the VP secretion increase 
induced by ADR. PNL (a β1+β2-receptor antagonist) before NADR 
administration prevented the VP secretion increase. ATL (a β1-receptor 
antagonist) did not block the VP secretion elevation induced by NADR. 
Surprisingly, the administration of PDL (a β1+β2-receptor antagonist) 
enhanced VP secretion. This contradictory effect can be explained in that PDL 
not only acts as a β-receptor blocker, but also exerts “intrinsic 
sympathomimetic action (ISA)” and a strong adrenergic agonist effect. GAL 
administration before ADR or NADR treatment prevented the VP level 
elevation induced by ADR or NADR. We concluded that mainly the α1- and 
β2-adrenergic receptors are involved in the ADR- or NADR-induced increase 
of VP secretion in isolated NH tissue cultures. The adrenergic control of VP 
secretion and the interactions between GAL and the adrenergic system can 
occur at the level of the posterior pituitary. 
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Summary 
The in vivo results suggest that GAL, as a peptide modulator, plays an 
important role in the regulation of VP secretion.  
Our in vitro experiments suggest that the GAL-ergic control of VP 
secretion and the interaction between GAL and the monoaminergic system in 
the NH tissue in rats can occur independently of the hypothalamus, at the level 
of the posterior pituitary. 
 With the results of our basic researches, we would like to contribute to 
better understanding of the function of hypothalamo-neurohypophyseal and 
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